NIH-Funded Research Identifies HDDC2 as Key Driver in Liver Cancer Progression, Influencing Patient Survival and Treatment Strategies
Research conducted under the auspices of the National Institutes of Health (NIH) has identified HDDC2 as a significant factor in the progression of hepatocellular carcinoma (HCC), the most common type of liver cancer. The study, which utilized data from The Cancer Genome Atlas (TCGA) and involved in-vitro and in-vivo experiments, found that HDDC2 is significantly overexpressed in HCC tissues and cell lines compared to normal controls. This overexpression is associated with shorter overall survival in HCC patients. A nomogram model, incorporating variables such as age, sex, stage, treatment, and HDDC2 expression, was developed to predict patient survival, showing moderate accuracy. The research also demonstrated that HDDC2 enhances the proliferation, migration, and invasion of HCC cells, and its knockdown significantly suppresses tumor growth in xenograft models. Furthermore, HDDC2 appears to promote HCC progression by modulating ribosomal function and activating the AKT/mTOR/S6K1 signaling pathway, a criti...